Megan McArdle

And how an upstart company may change that

The Continent’s problems are as much demographic as financial. They won’t go away soon.

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult and rare? The answer is often culture—the hardest thing of all to change.

Busted banking careers, crashed consultants, and shrunken incomes: the author attends her 10-year business-school reunion for lessons on how M.B.A.s can survive a recession.

The Republican contender touts his business experience—but does it really matter?

Are members of Congress guilty of insider trading—and does it matter?

We won’t stop the rising tide of infections until we develop a new business model to fight them.

Why the White House—and Washington—should miss departing economic adviser Austan Goolsbee

Why the man who runs the world's largest mutual fund sold all his Treasury bonds

High-end retailers are counting on us to spend more money on our kitchens— even as we spend less time in them.

Two of Wall Street's savviest value investors, Bruce Berkowitz and David Einhorn, pride themselves on their rigorous analysis. Now they're locked in a scorched-earth dispute over the value of some Florida real estate. How could they look at the same facts and reach such wildly different conclusions, and what does that say about the “value” of value investing?

How the U.S. invasion made Iraq’s economy worse, not better

Deep in debt, most governors will have to either raise taxes or cut spending— exactly what not to do when recovering from a recession.

Information technology is on the brink of revolutionizing health care— if physicians will only let it.

Buyers remain wary, and Washington is unlikely to recover all its bailout cash. But the colossus has slashed costs and spiffed up its cars—and is rejoining the global race.

Some small businesses are struggling to get credit, but that’s the least of their problems. Those that survive the recession will be stronger for it and lead the economy’s recovery.

Why the market’s rate of return—and your nest egg—may never recover

In 2009, only 25 new drugs were approved—less than half the number in the mid-’90s. Why are new pharmaceuticals so hard to bring to market? Overcautious regulators and profit-hungry conglomerates make easy scapegoats, but they’re only partly to blame. While we’re waiting for both sides to reinvent themselves, even little things like better monitoring of side effects can lead to big new discoveries.